Glaukos Corporation (GKOS)

39.34 +0.31 (+0.79%) At close: 04:00PM EDT

Glaukos Corporation

229 Avenida Fabricante
San Clemente, CA 92672
United States
949 367 9600
https://www.glaukos.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 727

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Thomas William Burns	Chairman & CEO	1.96M	12.84M	1961
Mr. Joseph E. Gilliam	Pres & COO	991.52k	2.43M	1977
Mr. Chris M. Calcaterra	Exec. VP of Global Commercial Operations	1M	4.34M	1960
Dr. Mory Gharib Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Alex R. Thurman	Sr. VP & CFO	N/A	N/A	1970
Mr. Christopher William Lewis	VP of Investor Relations & Corp. Affairs	N/A	N/A	N/A
Ms. Diane W. Biagianti	Sr. VP & Gen. Counsel	N/A	N/A	1960
Ms. Diana A. Scherer	VP of Compliance & Deputy Gen. Counsel	N/A	N/A	N/A
Ms. Michele M. Allegretto	Sr. VP of HR	N/A	N/A	N/A
Mr. David S. Haffner	Sr. VP of New Technologies	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Corporate Governance

Glaukos Corporation’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.